289 related articles for article (PubMed ID: 37033971)
1. Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.
Tischer-Zimmermann S; Bonifacius A; Santamorena MM; Mausberg P; Stoll S; Döring M; Kalinke U; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Front Immunol; 2023; 14():878953. PubMed ID: 37033971
[TBL] [Abstract][Full Text] [Related]
2. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
Subklewe M; Paludan C; Tsang ML; Mahnke K; Steinman RM; Münz C
J Exp Med; 2001 Feb; 193(3):405-11. PubMed ID: 11157061
[TBL] [Abstract][Full Text] [Related]
4. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
5. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.
Popescu I; Macedo C; Zeevi A; Nellis J; Patterson KR; Logar A; Rowe D; Reyes J; Rao AS; Storkus WJ; Fung JJ; Metes D
Am J Transplant; 2003 Nov; 3(11):1369-77. PubMed ID: 14525597
[TBL] [Abstract][Full Text] [Related]
9. Identification of Host Biomarkers of Epstein-Barr Virus Latency IIb and Latency III.
Messinger JE; Dai J; Stanland LJ; Price AM; Luftig MA
mBio; 2019 Jul; 10(4):. PubMed ID: 31266868
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells for the induction of EBV immunity.
Subklewe M
Recent Results Cancer Res; 2002; 159():38-43. PubMed ID: 11785842
[TBL] [Abstract][Full Text] [Related]
11. Induction of minor histocompatibility antigen-specific T-helper but not T-cytotoxic response is dependent on the source of antigen-presenting cell.
van Els CA; Bakker A; van Rood JJ; Goulmy E
Hum Immunol; 1990 May; 28(1):39-50. PubMed ID: 2160446
[TBL] [Abstract][Full Text] [Related]
12. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses.
Herr W; Ranieri E; Olson W; Zarour H; Gesualdo L; Storkus WJ
Blood; 2000 Sep; 96(5):1857-64. PubMed ID: 10961887
[TBL] [Abstract][Full Text] [Related]
13. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1.
Landais E; Saulquin X; Scotet E; Trautmann L; Peyrat MA; Yates JL; Kwok WW; Bonneville M; Houssaint E
Blood; 2004 Feb; 103(4):1408-16. PubMed ID: 14563644
[TBL] [Abstract][Full Text] [Related]
14. Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein by Epstein-Barr virus-transformed B-lymphoblastoid cell lines to CD4(+) T cells.
Chen M; Shirai M; Liu Z; Arichi T; Takahashi H; Nishioka M
J Virol; 1998 Oct; 72(10):8301-8. PubMed ID: 9733874
[TBL] [Abstract][Full Text] [Related]
15. Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells.
MacArthur GJ; Wilson AD; Birchall MA; Morgan AJ
J Virol; 2007 May; 81(9):4766-75. PubMed ID: 17314172
[TBL] [Abstract][Full Text] [Related]
16. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
17. Measurement of CD8+ and CD4+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs.
Sohn DH; Sohn HJ; Lee HJ; Lee SD; Kim S; Hyun SJ; Cho HI; Cho SG; Lee SK; Kim TG
PLoS One; 2015; 10(5):e0127899. PubMed ID: 26023769
[TBL] [Abstract][Full Text] [Related]
18. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
19. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
Santodonato L; D'Agostino G; Nisini R; Mariotti S; Monque DM; Spada M; Lattanzi L; Perrone MP; Andreotti M; Belardelli F; Ferrantini M
J Immunol; 2003 May; 170(10):5195-202. PubMed ID: 12734367
[TBL] [Abstract][Full Text] [Related]
20. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
Murray RJ; Kurilla MG; Brooks JM; Thomas WA; Rowe M; Kieff E; Rickinson AB
J Exp Med; 1992 Jul; 176(1):157-68. PubMed ID: 1319456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]